Six-month Treatment of Wet Age Related Macular Degeneration with Brolucizumab (Beovu) – a Case Series of Three Patients.

Wydanie 2/2021
str. 58 – 62

Autorzy: Dorota Luksa¹, Dorota Śpiewak¹, Katarzyna Michalska-Małecka^1,2

1 Oddział Okulistyki Dorosłych Uniwersyteckiego Centrum Klinicznego im. prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek
2. Klinika Okulistyki Katedry Okulistyki Wydziału Lekarskiego w Katowicach Śląskiego Uniwersytetu Medycznego w Katowicach
Kierownik: prof. dr hab. n. med. Ewa Mrukwa-Kominek

Summary: 

Age-related macular degeneration is a chronic, progressive degenerative disease of the macula, which mainly affects the population of people over sixty years of age and leads to impaired central vision. Anti-vascular endothelial growth factor therapy is now considered the “gold standard” in the treatment of the exudative form of age-related macular degeneration. The newest drug in this group, introduced to the market in February 2020, is broluzicumab (Beovu^® , Novartis).

In July 2020, eight patients were qualified for treatment with Brolucizumab at the Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice. Each patient was assessed for visual acuity according to Snellen charts, central retinal thickness by optical coherence tomography and the selected area with new vessels corresponding with active macular neovascularization and the flow area therethrough in optical coherence tomography angiography in the RTVue XR OCT Avanti system. Measurements were made on the day of injection and respectively seven days after receiving the antivascular endothelial growth factor intravitreal preparation. This article relates to six-month therapy in three selected patients. The effectiveness of Beovu has been confirmed for the treatment of patients with the exudative form of age-related macular degeneration. Visual acuity improved and stabilized, there was a decrease in the central retinal thickness and a decrease in the active macular neovascularization area including the flow area through it. There were no adverse effects among patients neither local nor systemic.